Boston Scientific Corporation (NYSE:BSX), a leading player in the medical technology sector, has been making waves in the industry with its innovative product pipeline and strong market performance.

Raymond James analyst Jayson Bedford raised the firm’s price target on Boston Scientific (BSX) to $122 from $119 and keeps a Strong Buy rating ...

Truist analyst Richard Newitter raised the firm’s price target on Boston Scientific (BSX) to $120 from $110 and keeps a Buy rating on the ...

Medical device company Boston Scientific (NYSE:BSX) reported Q4 CY2024 results beating Wall Street’s revenue expectations, with sales up 22.4% year on year to $4.56 billion. Guidance for next ...

Boston Scientific Corporation ( NYSE: BSX) Q4 2024 Earnings Conference Call February 5, 2025 8:00 AM ET Jonathan Monson - SVP, IR Michael Mahoney - Chairman and CEO Daniel Brennan - EVP and CFO ...

Boston Scientific posted Q4 revenue of $4.56 billion, surpassing estimates. The company forecasts 2025 sales growth of up to 14.5% and EPS of $2.80-$2.87.

Boston Scientific Corp. (NYSE ... particularly in patients with moderate to severe calcified arterial disease, an innovation that helped establish its name in 2019. According to the company ...

The addition of this system to our offerings can help us better serve physicians and their patients and provides a platform for future innovation," Lance Bates, Boston Scientific’s senior vice ...

Boston Scientific Corporation (NYSE:BSX), a leading player in the medical technology sector, has been making significant ...